Darren Veach
Darren Veach
Verified email at
Cited by
Cited by
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
B Nagar, WG Bornmann, P Pellicena, T Schindler, DR Veach, WT Miller, ...
Cancer research 62 (15), 4236-4243, 2002
Structural basis for the autoinhibition of c-Abl tyrosine kinase
B Nagar, O Hantschel, MA Young, K Scheffzek, D Veach, W Bornmann, ...
Cell 112 (6), 859-871, 2003
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
SP Gao, KG Mark, K Leslie, W Pao, N Motoi, WL Gerald, WD Travis, ...
The Journal of clinical investigation 117 (12), 3846-3856, 2007
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
CR Antonescu, KJ Busam, TD Francone, GC Wong, T Guo, NP Agaram, ...
International journal of cancer 121 (2), 257-264, 2007
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases
PM Reeves, B Bommarius, S Lebeis, S McNulty, J Christensen, A Swimm, ...
Nature medicine 11 (7), 731-739, 2005
Gleevec inhibits β-amyloid production but not Notch cleavage
WJ Netzer, F Dou, D Cai, D Veach, S Jean, Y Li, WG Bornmann, ...
Proceedings of the National Academy of Sciences 100 (21), 12444-12449, 2003
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases
D Wisniewski, CL Lambek, C Liu, A Strife, DR Veach, B Nagar, MA Young, ...
Cancer research 62 (15), 4244-4255, 2002
Two distinct phosphorylation pathways have additive effects on Abl family kinase activation
KQ Tanis, D Veach, HS Duewel, WG Bornmann, AJ Koleske
Molecular and cellular biology, 2003
Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor
T Guo, NP Agaram, GC Wong, G Hom, D D'Adamo, RG Maki, ...
Clinical Cancer Research 13 (16), 4874-4881, 2007
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
HG Wendel, E de Stanchina, E Cepero, S Ray, M Emig, JS Fridman, ...
Proceedings of the National Academy of Sciences 103 (19), 7444-7449, 2006
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
N Von Bubnoff, DR Veach, H Van Der Kuip, WE Aulitzky, J Sänger, ...
Blood 105 (4), 1652-1659, 2005
Enteropathogenic Escherichia coli Use Redundant Tyrosine Kinases to Form Actin Pedestals
A Swimm, B Bommarius, Y Li, D Cheng, P Reeves, M Sherman, D Veach, ...
Molecular biology of the cell 15 (8), 3520-3529, 2004
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare, CA Metcalf III, RS Bohacek, Y Wang, ...
Proceedings of the National Academy of Sciences 103 (24), 9244-9249, 2006
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
T Guo, M Hajdu, NP Agaram, H Shinoda, D Veach, BD Clarkson, RG Maki, ...
Clinical Cancer Research 15 (22), 6862-6870, 2009
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors
N Von Bubnoff, DR Veach, WT Miller, W Li, J Sänger, C Peschel, ...
Cancer research 63 (19), 6395-6404, 2003
Positron emission tomography/computed tomography–based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration …
JJ Fox, SC Gavane, E Blanc-Autran, S Nehmeh, M Gönen, B Beattie, ...
JAMA oncology 4 (2), 217-224, 2018
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation
X Deng, ER Hofmann, A Villanueva, O Hobert, P Capodieci, DR Veach, ...
Nature genetics 36 (8), 906-912, 2004
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia
NC Wolff, DR Veach, WP Tong, WG Bornmann, B Clarkson, RL Ilaria Jr
Blood 105 (10), 3995-4003, 2005
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
AJ Tipping, S Baluch, DJ Barnes, DR Veach, BM Clarkson, WG Bornmann, ...
Leukemia (08876924) 18 (8), 2004
Quantification of change in phosphorylation of BCR‐ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells
X Liang, M Hajivandi, D Veach, D Wisniewski, B Clarkson, MD Resh, ...
Proteomics 6 (16), 4554-4564, 2006
The system can't perform the operation now. Try again later.
Articles 1–20